FGFR2 and triple-negative breast carcinoma: FGFR2 fusions were reported to be present in up to 13% of liver cancers such as intrahepatic cholangiocarcinoma.638,639FGFR2 amplifications occur in triple-negative breast cancer, and are associated with high sensitivity to FGFR inhibitors.640 FGFR2 is shown to be associated with a higher risk of sporadic post-menopausal breast cancer.641 Amplifications of FGFR3 have been described rarely in cancer, while activation of FGFR3 by mutation was quite common.642 FGFR3 alterations (mutations or translocation) are among the most frequent genetic events in bladder carcinoma.